IHM
Iguana Healthcare Management Portfolio holdings
AUM
$133M
1-Year Return
45.66%
This Quarter Return
+15.77%
1 Year Return
+45.66%
3 Year Return
+127.07%
5 Year Return
–
10 Year Return
–
AUM
$175M
AUM Growth
+$19.1M
(+12%)
Cap. Flow
+$7.07M
Cap. Flow
% of AUM
4.04%
Top 10 Holdings %
Top 10 Hldgs %
36.73%
Holding
79
New
20
Increased
22
Reduced
18
Closed
11
Top Buys
| 1 |
Biogen
BIIB
|
$3.91M |
| 2 |
Bristol-Myers Squibb
BMY
|
$3.51M |
| 3 |
Danaher
DHR
|
$3M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$2.61M |
| 5 |
Esperion Therapeutics
ESPR
|
$2.51M |
Top Sells
| 1 |
SHPG
Shire pic
SHPG
|
$6.61M |
| 2 |
AGN
Allergan plc
AGN
|
$6.08M |
| 3 |
SPNC
Spectranetics Corp
SPNC
|
$4.22M |
| 4 |
Sanofi
SNY
|
$3.59M |
| 5 |
CELG
Celgene Corp
CELG
|
$3.28M |
Sector Composition
| 1 | Healthcare | 80.34% |
| 2 | Financials | 2.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sangamo Therapeutics
SGMO
$165M
| $3M | 1.63% |
200,000
-15,000
| -7% | -$225K |
|
|
XENT
27
DELISTED
Intersect ENT, Inc
XENT
| $2.8M | 1.53% |
90,000
+20,000
| +29% | +$623K |
|
28
Merus
MRUS
$5.1B
| $2.78M | 1.52% |
140,000
-35,000
| -20% | -$696K |
|
29
Ultragenyx Pharmaceutical
RARE
$3.07B
| $2.66M | 1.45% |
50,000
-25,000
| -33% | -$1.33M |
|
|
XLRN
30
DELISTED
Acceleron Pharma Inc.
XLRN
| $2.61M | 1.42% |
+70,000
| New | +$2.61M |
|
31
FibroGen
FGEN
$48.9M
| $2.15M | 1.17% |
+1,600
| New | +$2.15M |
|
32
Pfizer
PFE
$141B
| $2.14M | 1.17% |
+63,240
| New | +$2.14M |
|
|
CCXI
33
DELISTED
ChemoCentryx, Inc.
CCXI
| $2.04M | 1.11% |
275,000
+25,000
| +10% | +$186K |
|
|
CBAY
34
DELISTED
Cymabay Therapeutics
CBAY
| $2.02M | 1.1% |
250,000
+145,000
| +138% | +$1.17M |
|
35
Cardinal Health
CAH
$35.7B
| $2.01M | 1.09% |
+30,000
| New | +$2.01M |
|
36
AnaptysBio
ANAB
$613M
| $1.75M | 0.95% |
50,000
-20,000
| -29% | -$699K |
|
37
ADMA Biologics
ADMA
$4.03B
| $1.74M | 0.95% |
565,000
+415,000
| +277% | +$1.28M |
|
|
AVXS
38
DELISTED
AveXis, Inc. Common Stock
AVXS
| $1.69M | 0.92% |
17,500
-12,500
| -42% | -$1.21M |
|
|
ESRX
39
DELISTED
Express Scripts Holding Company
ESRX
| $1.58M | 0.86% |
+25,000
| New | +$1.58M |
|
|
OMED
40
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $1.58M | 0.86% |
350,000
-50,000
| -13% | -$226K |
|
41
Insmed
INSM
$30.7B
| $1.56M | 0.85% |
+50,000
| New | +$1.56M |
|
|
RXDX
42
DELISTED
Ignyta, Inc.
RXDX
| $1.54M | 0.84% |
125,000
+75,000
| +150% | +$926K |
|
|
ARNA
43
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.53M | 0.83% |
+60,000
| New | +$1.53M |
|
|
CORI
44
DELISTED
Corium International, Inc.
CORI
| $1.39M | 0.75% |
125,000
+25,000
| +25% | +$277K |
|
45
Kura Oncology
KURA
$713M
| $1.35M | 0.73% |
+90,000
| New | +$1.35M |
|
46
CytomX Therapeutics
CTMX
$376M
| $1.27M | 0.69% |
70,000
+10,000
| +17% | +$182K |
|
|
DPLO
47
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $1.24M | 0.68% |
60,000
-15,000
| -20% | -$311K |
|
|
CTLT
48
DELISTED
CATALENT, INC.
CTLT
| $1.2M | 0.65% |
+30,000
| New | +$1.2M |
|
49
Wave Life Sciences
WVE
$1.32B
| $1.2M | 0.65% |
55,000
| – | – |
|
50
Teladoc Health
TDOC
$1.38B
| $1.16M | 0.63% |
+35,000
| New | +$1.16M |
|